Jeffrey Krasner is a senior life science and healthcare communications executive. He is an award-winning writer with broad knowledge of the regulatory environment, drug development, government-funded research, clinical trials, state and federal healthcare reform, and issues facing drugmakers, healthcare payers and providers.
Mr. Krasner is founder and president of Watertown, MA-based Emerging BioCommunications, a PR agency geared specifically for startup and growing life science companies. His selected clients include: Syntimmune, Pippin Therapeutics, Elstar Therapeutics, The Collaborative Trajectory Analysis Project (cTAP), BioProcess Technology Consultants, Paradigm4, Frequency Therapeutics, Seventh Sense Biosystems.
Prior to founding BioCommunications, Mr. Krasner served as senior director of communications at Flagship Ventures, where he established and executed communications strategy for $1.4 billion venture fund active in therapeutics, life sciences, and sustainability. He also served as a reporter specializing in healthcare, healthcare reform, biotechnology and medical devices for The Boston Globe (2001-2009); Boston Globe Spotlight Team Investigation of Partners Healthcare Pricing (2008); Reporter, The Wall Street Journal (1997-2000); Assistant business editor and columnist, Boston Herald (1984-1997); Reporter, San Jose Business Journal (1983-1984).